Pharmaceutical Technology

MAY 29, 2023

The global pharmaceutical industry experienced a 17% rise in company filings mentions of blockchain in Q1 2023 compared with the previous quarter, with the highest share accounted for by Bayer, according to GlobalData’s analysis of over 60 pharmaceutical company filings. Starting at 100 in 2020, an index over 100 is more positive.

Pharmaceutical 52

Pharmaceutical Competition Marketing Medicine 52

Pharmaceutical Technology

JUNE 21, 2023

In the past year, Hemgenix has been granted approval by the US Food and Drug Administration (FDA) and has received conditional marketing authorisation from the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). GlobalData is the parent company of Pharmaceutical Technology.

Patients 98

Patients Food and Drug Administration Engineering Sales 98

Pharmaceutical Technology

MARCH 31, 2023

This also demonstrates our confidence in the investment climate in Kenya and the importance of utilising mRNA technology to build resilience in healthcare security in Africa.” The company is also committed to establishing mRNA manufacturing facilities in Australia, Canada, the US and the UK.

Manufacturing 105

Manufacturing Government Medicine Healthcare 105

pharmaphorum

JANUARY 5, 2023

Despite the RSV vaccine threat, analysts at GlobalData have predicted that nirsevimab could reach $3 billion in annual revenue by 2030, assuming a launch in both Europe and the US this year. The post FDA starts review of Sanofi, AZ antibody for RSV prevention appeared first on.

FDA 52

FDA Healthcare Provider Marketing Healthcare 52

Medico Reach

FEBRUARY 8, 2023

Hence, looking closer at the future trends in pharma industry only makes sense for businesses to stay afloat in the healthcare market. from 2022 to 2030, the pharma industry will reach USD 9,241.34 million by 2030. from 2023 to 2030. Poised to grow at a CAGR of 29.4% billion in 2022 and will expand at a CAGR of 10.3%

Pharma 52

Pharma Medicine Marketing Prospecting 52

pharmaphorum

SEPTEMBER 16, 2022

Pfizer is currently leading the race to bring an RSV vaccine to market for use by expectant mothers, which would transfer protection to newborns and infants, with phase 3 results due next year. Its closest rival GSK suffered a setback when it was forced to abandon phase 3 trials of its candidate on safety grounds earlier this year.

Marketing 57

Marketing Leads Safety Manufacturing 57

European Pharmaceutical Review

MARCH 24, 2023

According to GlobalData, competition to develop a first-to-market drug for NASH is strong. In NASH, excess fat in the liver can lead to progressive disease, including inflammation, liver cell injury and fibrosis, which are associated with increased risk for cardiovascular disease and liver morbidity and mortality.

Medical 82

Medical Side effects Safety Pharmaceutical 82